Gujrati et al., established the AffiHER2 OMV vaccine by utilizing siRNA to target kinesin spindle protein and select human epidermal growth factor receptor 2 (HER2) as the receptor in tumor cells [105]. This evidence concerns the gene ERBB2 and neoplasm.